These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 22902364)

  • 21. A contribution to examination of propidium iodide and annexin V plasma cells indices in multiple myeloma.
    Scudla V; Ordeltova M; Bacovsky J; Vytrasova M; Sumna E; Martinek A; Horak P
    Neoplasma; 2003; 50(5):363-71. PubMed ID: 14628090
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increased circulating plasma cells detected by flow cytometry predicts poor prognosis in patients with plasma cell myeloma.
    Bae MH; Park CJ; Kim BH; Cho YU; Jang S; Lee DH; Seo EJ; Yoon DH; Lee JH; Suh C
    Cytometry B Clin Cytom; 2018 May; 94(3):493-499. PubMed ID: 29220877
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Significant changes in diagnostic and therapeutic procedures in smoldering multiple myeloma].
    Jurczyszyn A; Olszewska-Szopa M; Skotnicki AB
    Przegl Lek; 2015; 72(11):642-8. PubMed ID: 27012123
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.
    Sørrig R; Klausen TW; Salomo M; Vangsted AJ; Østergaard B; Gregersen H; Frølund UC; Andersen NF; Helleberg C; Andersen KT; Pedersen RS; Pedersen P; Abildgaard N; Gimsing P;
    Eur J Haematol; 2016 Sep; 97(3):303-9. PubMed ID: 26710662
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Circulating peripheral blood plasma cells in multiple myeloma.
    Witzig TE; Kyle RA; Greipp PR
    Curr Top Microbiol Immunol; 1992; 182():195-9. PubMed ID: 1490354
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Smoldering multiple myeloma.
    Rajkumar SV; Landgren O; Mateos MV
    Blood; 2015 May; 125(20):3069-75. PubMed ID: 25838344
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mode of progression in smoldering multiple myeloma: a study of 406 patients.
    Abdallah NH; Lakshman A; Kumar SK; Cook J; Binder M; Kapoor P; Dispenzieri A; Gertz MA; Lacy MQ; Hayman SR; Buadi FK; Dingli D; Lin Y; Kourelis T; Warsame R; Bergsagel L; Rajkumar SV
    Blood Cancer J; 2024 Jan; 14(1):9. PubMed ID: 38228628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Utility of hematology analyzer and flow cytometry in timely and correct detection of circulating plasma cells: Report of three cases.
    Gounari E; Tsavdaridou V; Koletsa T; Nikolaidou A; Kaiafa G; Papaioannou M; Kostopoulos I; Skoura L
    Cytometry B Clin Cytom; 2016 Nov; 90(6):531-537. PubMed ID: 26663635
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating Tumor and Immune Cells for Minimally Invasive Risk Stratification of Smoldering Multiple Myeloma.
    Termini R; Žihala D; Terpos E; Perez-Montaña A; Jelínek T; Raab M; Weinhold N; Mai EK; Grab AL; Corre J; Vergez F; Sacco A; Chiarini M; Giustini V; Tucci A; Rodriguez S; Moreno C; Perez C; Maia C; Martín-Sánchez E; Guerrero C; Botta C; Garces JJ; Lopez A; Tamariz-Amador LE; Prosper F; Bargay J; Cabezudo ME; Ocio EM; Hájek R; Martinez-Lopez J; Solano F; Iglesias R; Paiva A; Geraldes C; Vitoria H; Gomez C; De Arriba F; Ludwig H; Garcia-Guiñon A; Casanova M; Alegre A; Cabañas V; Sirvent M; Oriol A; de la Rubia J; Hernández-Rivas JÁ; Palomera L; Sarasa M; Rios P; Puig N; Mateos MV; Flores-Montero J; Orfao A; Goldschmidt H; Avet-Loiseau H; Roccaro AM; San-Miguel JF; Paiva B;
    Clin Cancer Res; 2022 Nov; 28(21):4771-4781. PubMed ID: 36074126
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Detailed characterization of multiple myeloma circulating tumor cells shows unique phenotypic, cytogenetic, functional, and circadian distribution profile.
    Paiva B; Paino T; Sayagues JM; Garayoa M; San-Segundo L; Martín M; Mota I; Sanchez ML; Bárcena P; Aires-Mejia I; Corchete L; Jimenez C; Garcia-Sanz R; Gutierrez NC; Ocio EM; Mateos MV; Vidriales MB; Orfao A; San Miguel JF
    Blood; 2013 Nov; 122(22):3591-8. PubMed ID: 24072855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical significance of CD81 expression by clonal plasma cells in high-risk smoldering and symptomatic multiple myeloma patients.
    Paiva B; Gutiérrez NC; Chen X; Vídriales MB; Montalbán MÁ; Rosiñol L; Oriol A; Martínez-López J; Mateos MV; López-Corral L; Díaz-Rodríguez E; Pérez JJ; Fernández-Redondo E; de Arriba F; Palomera L; Bengoechea E; Terol MJ; de Paz R; Martin A; Hernández J; Orfao A; Lahuerta JJ; Bladé J; Pandiella A; Miguel JF;
    Leukemia; 2012 Aug; 26(8):1862-9. PubMed ID: 22333880
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The road to treating smoldering multiple myeloma.
    Korde N; Mailankody S; Landgren O
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S59-64. PubMed ID: 25486957
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic analysis of high-risk smoldering multiple myeloma.
    López-Corral L; Mateos MV; Corchete LA; Sarasquete ME; de la Rubia J; de Arriba F; Lahuerta JJ; García-Sanz R; San Miguel JF; Gutiérrez NC
    Haematologica; 2012 Sep; 97(9):1439-43. PubMed ID: 22331267
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Progress in the Management of Smoldering Multiple Myeloma.
    Schmidt TM; Callander NS
    Curr Hematol Malig Rep; 2021 Apr; 16(2):172-182. PubMed ID: 33983517
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The Changing Landscape of Smoldering Multiple Myeloma: A European Perspective.
    Caers J; Fernández de Larrea C; Leleu X; Heusschen R; Zojer N; Decaux O; Kastritis E; Minnema M; Jurczyszyn A; Beguin Y; Wäsch R; Palumbo A; Dimopoulos M; Mateos MV; Ludwig H; Engelhardt M
    Oncologist; 2016 Mar; 21(3):333-42. PubMed ID: 26921288
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Monoclonal plasma cells in the blood stem cell harvest from patients with multiple myeloma are associated with shortened relapse-free survival after transplantation.
    Gertz MA; Witzig TE; Pineda AA; Greipp PR; Kyle RA; Litzow MR
    Bone Marrow Transplant; 1997 Feb; 19(4):337-42. PubMed ID: 9051243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blood monitoring of circulating tumor plasma cells by next generation flow in multiple myeloma after therapy.
    Sanoja-Flores L; Flores-Montero J; Puig N; Contreras-Sanfeliciano T; Pontes R; Corral-Mateos A; García-Sánchez O; Díez-Campelo M; Pessoa de Magalhães RJ; García-Martín L; Alonso-Alonso JM; García-Mateo A; Aguilar-Franco C; Labrador J; Barez-García A; Maiolino A; Paiva B; San Miguel J; Sobral da Costa E; González M; Mateos MV; Durie B; van Dongen JJM; Orfao A
    Blood; 2019 Dec; 134(24):2218-2222. PubMed ID: 31697808
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.